PIK3CA-RELATED OVERGROWTH SPECTRUM (PROS)
Clinical trials for PIK3CA-RELATED OVERGROWTH SPECTRUM (PROS) explained in plain language.
Never miss a new study
Get alerted when new PIK3CA-RELATED OVERGROWTH SPECTRUM (PROS) trials appear
Sign up with your email to follow new studies for PIK3CA-RELATED OVERGROWTH SPECTRUM (PROS), keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New drug targets root cause of rare overgrowth diseases in kids and adults
Disease control Recruiting nowThis study tests a new drug, RLY-2608, designed to block a faulty protein that causes abnormal growth in people with PIK3CA-related overgrowth spectrum (PROS) and related malformations. The trial enrolls 277 adults and children to see if the drug can safely shrink overgrown tissu…
Matched conditions: PIK3CA-RELATED OVERGROWTH SPECTRUM (PROS)
Phase: PHASE2 • Sponsor: Relay Therapeutics, Inc. • Aim: Disease control
Last updated May 15, 2026 11:55 UTC
-
Desperate patients get early access to promising cancer drug
Disease control AVAILABLEThis program provides early access to the drug alpelisib (BYL719) for people with PIK3CA-related overgrowth spectrum (PROS) or breast cancer who have no other treatment options and cannot join a clinical trial. Doctors must request the drug for individual patients who may benefit…
Matched conditions: PIK3CA-RELATED OVERGROWTH SPECTRUM (PROS)
Sponsor: Novartis Pharmaceuticals • Aim: Disease control
Last updated May 14, 2026 12:02 UTC
-
New targeted drug shows promise for rare growth disorders
Disease control Recruiting nowThis study tests a new drug called CYH33 in people with rare conditions that cause abnormal growth of body parts or blood vessels. The drug targets a specific genetic change to help shrink overgrown tissue. The trial involves 141 adults and teens and will check for safety and eff…
Matched conditions: PIK3CA-RELATED OVERGROWTH SPECTRUM (PROS)
Phase: PHASE1, PHASE2 • Sponsor: Haihe Biopharma Co., Ltd. • Aim: Disease control
Last updated May 11, 2026 20:53 UTC
-
New hope for rare overgrowth disorder: alpelisib trial targets root cause
Disease control Recruiting nowThis study tests an oral drug, alpelisib, in children and adults with PIK3CA-related overgrowth spectrum (PROS), a rare condition causing abnormal tissue growth. The goal is to shrink overgrown tissue and improve symptoms. About 104 participants aged 2 and older will take the dru…
Matched conditions: PIK3CA-RELATED OVERGROWTH SPECTRUM (PROS)
Phase: PHASE2 • Sponsor: Novartis Pharmaceuticals • Aim: Disease control
Last updated May 06, 2026 16:01 UTC